Clarithromycin/clofazimine/rifabutin - RedHill Biopharma

Drug Profile

Clarithromycin/clofazimine/rifabutin - RedHill Biopharma

Alternative Names: Clarithromycin/rifabutin/clofazimine; Clofazimine/clarithromycin/rifabutin; Clofazimine/rifabutin/clarithromycin; Myoconda®; RHB-104; Rifabutin/clarithromycin/clofazimine; Rifabutin/clofazimine/clarithromycin

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centre for Digestive Diseases
  • Developer RedHill Biopharma
  • Class Antibacterials; Macrolides; Phenazines; Rifamycins
  • Mechanism of Action Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity No

Highest Development Phases

  • Phase III Crohn's disease
  • Phase II Multiple sclerosis
  • Preclinical Mycobacterial infections; Psoriasis; Type 1 diabetes mellitus
  • No development reported Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 13 Nov 2017 Redhill Biopharma plans a pivotal phase III trial for Mycobacterial infections (nontuberculous mycobacteria) in USA in the first half of 2018
  • 09 Nov 2017 RedHill Pharma completes enrolment in the phase III MAP US trial in Crohn's disease in USA, Europe, Canada, Israel, Australia and New Zealand (NCT01951326)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Israel (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top